Relyea Zuckerberg Hanson LLC Cuts Stock Position in Danaher Corporation $DHR

Relyea Zuckerberg Hanson LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 41.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,122 shares of the conglomerate’s stock after selling 783 shares during the quarter. Relyea Zuckerberg Hanson LLC’s holdings in Danaher were worth $222,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. boosted its position in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the period. Sierra Ocean LLC raised its stake in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Red Tortoise LLC boosted its holdings in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher during the 1st quarter worth $31,000. Finally, Dunhill Financial LLC increased its holdings in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Down 1.6%

NYSE DHR opened at $211.65 on Tuesday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The company has a market capitalization of $151.55 billion, a price-to-earnings ratio of 45.03, a price-to-earnings-growth ratio of 3.06 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm’s fifty day moving average price is $200.36 and its 200 day moving average price is $197.24.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the company posted $1.72 earnings per share. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is currently 27.23%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DHR. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Danaher in a report on Saturday, September 27th. Bank of America dropped their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Finally, Evercore ISI dropped their target price on Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $245.91.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.